Regulation - Pricing, Antibiotics and Infectious diseases


Popular Filters

IQWiG finds no added proven benefit for Astellas' fidaxomicin in Clostridium difficile infection


In an early benefit assessment under Germany's Act on the Reform of the Market for Medicinal Products…

Antibiotics and Infectious diseasesAstellas PharmaDificidDificlirfidaxomicinPharmaceuticalPricingRegulation

Preliminary NICE guidance negative on Pfizer's Xalkori for lung cancer; backs Colobreathe and Tobi Podhaler for CF


Much to the disappointment of the company, this morning (March 27), UK drugs watchdog the National Institute…

Antibiotics and Infectious diseasesColoBreatheEuropeForest LaboratoriesNovartisOncologyPfizerPharmaceuticalPricingRare diseasesRegulationTobi PodhalerXalkori

NICE "green light" for Novartis' Tobi Podhaler and Forest's Colobreathe


The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in a final draft…

Antibiotics and Infectious diseasesColoBreatheEuropeForest LaboratoriesNovartisPharmaceuticalPricingRare diseasesRegulationTobi Podhaler

Back to top